Skip to main content
. Author manuscript; available in PMC: 2024 Jan 5.
Published in final edited form as: Clin Cancer Res. 2023 Jul 5;29(13):2351–2361. doi: 10.1158/1078-0432.CCR-22-0283

Figure 2. Pan-cancer prevalence of HER2 alterations (mutations and amplifications).

Figure 2.

Panel A shows ERBB2 alterations seen in 6% of 85,575 patients with diverse cancers as per the cancer genomic data aggregated through AACR Project Genomics Evidence Neoplasia Information Exchange (GENIE) effort (AACR Genie v11.0-public). Only tumor types with ≥ 10 cases and at least 1% prevalence were included. Panel B shows the oncoprint in the same cohort and highlights the type of mutations seen in these patients with limited overlap of mutations and amplifications.